Additional patient characteristics
| Patient groups . | N . | Study entry . | Day of procedure . | ||
|---|---|---|---|---|---|
| HIV RNA median copies/mL (range) . | CD4 median cells/μL (range) . | HIV RNA median copies/mL (range) . | CD4 median cells/μL (range) . | ||
| Fiebig stage I-II | 2 | 1 250 000 (500 000-2 000 000) | 419 | 980 000 (100 000-1 860 000) | 399 (269-529) |
| Fiebig stage III-IV | 4 | 421 227 (754-2 850 000) | 729 (426-1032) | 39 257 (1280-920 000) | 611 (464-679) |
| Fiebig stage V-VI | 20 | 76 800 (2010-3 560 000) | 586 (330-1074) | 28 900 (377-1 060 000) | 540 (320-1066) |
| Patient groups . | N . | Study entry . | Day of procedure . | ||
|---|---|---|---|---|---|
| HIV RNA median copies/mL (range) . | CD4 median cells/μL (range) . | HIV RNA median copies/mL (range) . | CD4 median cells/μL (range) . | ||
| Fiebig stage I-II | 2 | 1 250 000 (500 000-2 000 000) | 419 | 980 000 (100 000-1 860 000) | 399 (269-529) |
| Fiebig stage III-IV | 4 | 421 227 (754-2 850 000) | 729 (426-1032) | 39 257 (1280-920 000) | 611 (464-679) |
| Fiebig stage V-VI | 20 | 76 800 (2010-3 560 000) | 586 (330-1074) | 28 900 (377-1 060 000) | 540 (320-1066) |